• +1-646-491-9876
    • +91-20-67278686

    Search

    Bladder Cancer-Pipeline Review H1 2017

    Bladder Cancer-Pipeline Review H1 2017

    • Report Code ID: RW0001834386
    • Category Pharmaceuticals
    • No. of Pages 801
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Bladder Cancer - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H1 2017, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

    Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 51, 43, 1, 52 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 11 and 2 molecules, respectively.

    Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 7
    Bladder Cancer - Overview 8
    Bladder Cancer - Therapeutics Development 9
    Bladder Cancer - Therapeutics Assessment 32
    Bladder Cancer - Companies Involved in Therapeutics Development 50
    Bladder Cancer - Drug Profiles 108
    Bladder Cancer - Dormant Projects 759
    Bladder Cancer - Discontinued Products 765
    Bladder Cancer - Product Development Milestones 767
    Appendix 781

    List of Tables

    Number of Products under Development for Bladder Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Bladder Cancer - Pipeline by 4SC AG, H1 2017
    Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
    Bladder Cancer - Pipeline by ADC Therapeutics Sarl, H1 2017
    Bladder Cancer - Pipeline by Agenus Inc, H1 2017
    Bladder Cancer - Pipeline by Altor BioScience Corp, H1 2017
    Bladder Cancer - Pipeline by AndroScience Corp, H1 2017
    Bladder Cancer - Pipeline by ANP Technologies Inc, H1 2017
    Bladder Cancer - Pipeline by APIM Therapeutics AS, H1 2017
    Bladder Cancer - Pipeline by Archivel Farma SL, H1 2017
    Bladder Cancer - Pipeline by Argos Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Arno Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Array BioPharma Inc, H1 2017
    Bladder Cancer - Pipeline by Asana BioSciences LLC, H1 2017
    Bladder Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2017
    Bladder Cancer - Pipeline by Astellas Pharma Inc, H1 2017
    Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by AstraZeneca Plc, H1 2017
    Bladder Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by Bavarian Nordic A/S, H1 2017
    Bladder Cancer - Pipeline by Bayer AG, H1 2017
    Bladder Cancer - Pipeline by BioCancell Ltd, H1 2017
    Bladder Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
    Bladder Cancer - Pipeline by Bioncotech Therapeutics SL, H1 2017
    Bladder Cancer - Pipeline by Biotest AG, H1 2017
    Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Bladder Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Bladder Cancer - Pipeline by Celgene Corp, H1 2017
    Bladder Cancer - Pipeline by Cellceutix Corp, H1 2017
    Bladder Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Celprogen Inc, H1 2017
    Bladder Cancer - Pipeline by Celsion Corp, H1 2017
    Bladder Cancer - Pipeline by Celyad SA, H1 2017
    Bladder Cancer - Pipeline by Cold Genesys Inc, H1 2017
    Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Eisai Co Ltd, H1 2017
    Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Eli Lilly and Company, H1 2017
    Bladder Cancer - Pipeline by Elsalys Biotech SAS, H1 2017
    Bladder Cancer - Pipeline by EpiThany Inc, H1 2017
    Bladder Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by Exelixis Inc, H1 2017
    Bladder Cancer - Pipeline by Exicure Inc, H1 2017
    Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Bladder Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by For-Robin Inc, H1 2017
    Bladder Cancer - Pipeline by Gene Signal International SA, H1 2017
    Bladder Cancer - Pipeline by Genmab A/S, H1 2017
    Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
    Bladder Cancer - Pipeline by H3 Biomedicine Inc, H1 2017
    Bladder Cancer - Pipeline by Hamlet Pharma AB, H1 2017
    Bladder Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Bladder Cancer - Pipeline by HitGen LTD, H1 2017
    Bladder Cancer - Pipeline by Horizon Pharma Plc, H1 2017
    Bladder Cancer - Pipeline by Idera Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by Immunocore Ltd, H1 2017
    Bladder Cancer - Pipeline by Immunomedics Inc, H1 2017
    Bladder Cancer - Pipeline by Immupharma Plc, H1 2017
    Bladder Cancer - Pipeline by Incanthera Ltd, H1 2017
    Bladder Cancer - Pipeline by Incyte Corp, H1 2017
    Bladder Cancer - Pipeline by InteRNA Technologies BV, H1 2017
    Bladder Cancer - Pipeline by Johnson & Johnson, H1 2017
    Bladder Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2017
    Bladder Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
    Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc, H1 2017
    Bladder Cancer - Pipeline by MacroGenics Inc, H1 2017
    Bladder Cancer - Pipeline by Marina Biotech Inc, H1 2017
    Bladder Cancer - Pipeline by MaxiVAX SA, H1 2017
    Bladder Cancer - Pipeline by Meabco A/S, H1 2017
    Bladder Cancer - Pipeline by Medicenna Therapeutics Corp, H1 2017
    Bladder Cancer - Pipeline by MedImmune LLC, H1 2017
    Bladder Cancer - Pipeline by Merck & Co Inc, H1 2017
    Bladder Cancer - Pipeline by Merck KGaA, H1 2017
    Bladder Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Moleculin Biotech Inc, H1 2017
    Bladder Cancer - Pipeline by MTG Biotherapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017
    Bladder Cancer - Pipeline by Nektar Therapeutics, H1 2017
    Bladder Cancer - Pipeline by Omeros Corp, H1 2017
    Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by OncoTherapy Science Inc, H1 2017
    Bladder Cancer - Pipeline by Oncovir Inc, H1 2017
    Bladder Cancer - Pipeline by Optimum Therapeutics LLC, H1 2017
    Bladder Cancer - Pipeline by Pfizer Inc, H1 2017
    Bladder Cancer - Pipeline by Pharma Mar SA, H1 2017
    Bladder Cancer - Pipeline by Philogen SpA, H1 2017
    Bladder Cancer - Pipeline by Plexxikon Inc, H1 2017
    Bladder Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by Provecs Medical GmbH, H1 2017
    Bladder Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by PsiOxus Therapeutics Ltd, H1 2017
    Bladder Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by Samyang Biopharmaceuticals Corp, H1 2017
    Bladder Cancer - Pipeline by Sanofi, H1 2017
    Bladder Cancer - Pipeline by Sareum Holdings Plc, H1 2017
    Bladder Cancer - Pipeline by Shionogi & Co Ltd, H1 2017
    Bladder Cancer - Pipeline by Sierra Oncology Inc, H1 2017
    Bladder Cancer - Pipeline by Sillajen Biotherapeutics, H1 2017
    Bladder Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by Stemline Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Bladder Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
    Bladder Cancer - Pipeline by Taris Biomedical LLC, H1 2017
    Bladder Cancer - Pipeline by Theralase Technologies Inc, H1 2017
    Bladder Cancer - Pipeline by Theravectys SA, H1 2017
    Bladder Cancer - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
    Bladder Cancer - Pipeline by Transgene SA, H1 2017
    Bladder Cancer - Pipeline by UroGen Pharmaceuticals Ltd, H1 2017
    Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H1 2017
    Bladder Cancer - Pipeline by Vault Pharma Inc, H1 2017
    Bladder Cancer - Pipeline by Vaxeal Holding SA, H1 2017
    Bladder Cancer - Pipeline by Vaxiion Therapeutics Inc, H1 2017
    Bladder Cancer - Pipeline by Viralytics Ltd, H1 2017
    Bladder Cancer - Dormant Projects, H1 2017
    Bladder Cancer - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Bladder Cancer - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Bladder Cancer - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Bladder Cancer - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Bladder Cancer - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Bladder Cancer - Discontinued Products, H1 2017
    Bladder Cancer - Discontinued Products, H1 2017 (Contd..1) , H1 2017

    List of Figures

    Number of Products under Development for Bladder Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    4SC AG
    Adaptimmune Therapeutics Plc
    ADC Therapeutics Sarl
    Agenus Inc
    Altor BioScience Corp
    AndroScience Corp
    ANP Technologies Inc
    APIM Therapeutics AS
    Archivel Farma SL
    Argos Therapeutics Inc
    Arno Therapeutics Inc
    Array BioPharma Inc
    Asana BioSciences LLC
    Asieris Pharmaceuticals Co Ltd
    Astellas Pharma Inc
    Astex Pharmaceuticals Inc
    AstraZeneca Plc
    AVEO Pharmaceuticals Inc
    Bavarian Nordic A/S
    Bayer AG
    BioCancell Ltd
    Biomics Biotechnologies Co Ltd
    Bioncotech Therapeutics SL
    Biotest AG
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Celgene Corp
    Cellceutix Corp
    Celldex Therapeutics Inc
    Celprogen Inc
    Celsion Corp
    Celyad SA
    Cold Genesys Inc
    Corvus Pharmaceuticals Inc
    CytomX Therapeutics Inc
    Cytori Therapeutics Inc
    Eisai Co Ltd
    Eleven Biotherapeutics Inc
    Eli Lilly and Company
    Elsalys Biotech SAS
    EpiThany Inc
    Esperance Pharmaceuticals Inc
    Exelixis Inc
    Exicure Inc
    F. Hoffmann-La Roche Ltd
    Five Prime Therapeutics Inc
    For-Robin Inc
    Gene Signal International SA
    Genmab A/S
    GlaxoSmithKline Plc
    H3 Biomedicine Inc
    Hamlet Pharma AB
    Hanmi Pharmaceuticals Co Ltd
    HitGen LTD
    Horizon Pharma Plc
    Idera Pharmaceuticals Inc
    Immunocore Ltd
    Immunomedics Inc
    Immupharma Plc
    Incanthera Ltd
    Incyte Corp
    InteRNA Technologies BV
    Johnson & Johnson
    Laboratoires Pierre Fabre SA
    Lion Biotechnologies Inc
    LipoMedix Pharmaceutical Inc
    MacroGenics Inc
    Marina Biotech Inc
    MaxiVAX SA
    Meabco A/S
    Medicenna Therapeutics Corp
    MedImmune LLC
    Merck & Co Inc
    Merck KGaA
    Mirati Therapeutics Inc
    Moleculin Biotech Inc
    MTG Biotherapeutics Inc
    NanoCarrier Co Ltd
    Nektar Therapeutics
    Omeros Corp
    Oncogenex Pharmaceuticals Inc
    OncoTherapy Science Inc
    Oncovir Inc
    Optimum Therapeutics LLC
    Pfizer Inc
    Pharma Mar SA
    Philogen SpA
    Plexxikon Inc
    Polaris Pharmaceuticals Inc
    Provecs Medical GmbH
    Provectus Biopharmaceuticals Inc
    PsiOxus Therapeutics Ltd
    Rexahn Pharmaceuticals Inc
    Samyang Biopharmaceuticals Corp
    Sanofi
    Sareum Holdings Plc
    Shionogi & Co Ltd
    Sierra Oncology Inc
    Sillajen Biotherapeutics
    Sorrento Therapeutics Inc
    Spectrum Pharmaceuticals Inc
    Stemline Therapeutics Inc
    Sun Pharma Advanced Research Company Ltd
    Taiwan Liposome Company Ltd
    Taris Biomedical LLC
    Theralase Technologies Inc
    Theravectys SA
    Tolero Pharmaceuticals Inc
    Transgene SA
    UroGen Pharmaceuticals Ltd
    Vakzine Projekt Management GmbH
    Vault Pharma Inc
    Vaxeal Holding SA
    Vaxiion Therapeutics Inc
    Viralytics Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//bladder-cancer-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//bladder-cancer-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//bladder-cancer-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments